Scandion Oncology is building a pipeline of drugs that can revert cancer drug resistance through different mechanisms
Our Clinical Pipeline
Scandion Oncology has two programs in clinical development with our first-in-class lead compound SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is a clinical phase II study. The second program, PANTAX, for the treatment of unresectable or metastatic pancreatic cancer is a clinical phase Ib study.
Our Pre-clinical Pipeline
Scandion Oncology is building a pre-clinical pipeline of drugs that can revert cancer drug resistance through different mechanisms, to increasingly broaden the offering of medicines able to combat various types of cancer drug resistance.
Currently on hold